Evidence map›Paper›PMID 42251173›Full record

ArticleBone marrow transplantation2026

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Guillaume Dachy, Jarl E Mooyaart, Ludovic Gabellier, Ibrahim Yakoub-Agha, Michael Daskalakis, Victoria Potter, Peter Dreger, Anne Huynh, Christof Scheid, Matthew Collin and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Guillaume DachyCliniques Universitaires St. Luc, Brussels, Belgium.ORCID http://orcid.org/0000-0002-1668-975X
Jarl E MooyaartEBMT Leiden Study Unit, Leiden, The Netherlands.
Ludovic GabellierHôpital Saint-Eloi, CHU de Montpellier, Montpellier, France.
Ibrahim Yakoub-AghaCHU de Lille, Lille, France.ORCID http://orcid.org/0000-0003-4524-8782
Michael DaskalakisUniversity Hospital Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-8138-0505
Victoria PotterKings College Hospital London, London, UK.
Peter DregerUniversity of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7429-8570
Anne HuynhCHU - Institut Universitaire du Cancer Toulouse, Toulouse, France.
Christof ScheidUniversity Hospital Cologne, Cologne, Germany.ORCID http://orcid.org/0009-0007-6539-226X
Matthew CollinRVI Newcastle, Newcastle, UK.
Gabriel BrisouHematology department, Paoli Calmettes Institute, Marseille, France.
Gerald WulfUniversity Hospital Goettingen, Goettingen, Germany.
Rachel ProtheroeUniversity Hospitals Bristol and Weston NHSFT, Bristol, UK.
Carlos Solano VercetHospital Clínico de Valencia, Valencia, Spain.
Lucía López-CorralHospital Clínico, Salamanca, Spain.ORCID http://orcid.org/0000-0003-1908-5596
Peter VandenbergheUniversity Hospital Gasthuisberg, Leuven, Belgium.ORCID http://orcid.org/0000-0003-4719-1935
Francis AyukUniversity Hospital Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-6297-1847
Stefania BramantiIRCCS Istituto Clinico Humanitas, Rozzano, Italy.
Marjolein van der PoelUniversity Hospital Maastricht, Maastricht, The Netherlands.
Jorinde D HoogenboomEBMT Leiden Study Unit, Leiden, The Netherlands.
Jürgen KuballUniversity Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-3914-7806
Annalisa RuggeriSan Raffaele Scientific Institute, Hematology and Bone Marrow Transplantation Unit, Milan, Italy. annalisaruggeri80@hotmail.com.ORCID http://orcid.org/0000-0002-7261-2765
Florent MalardHôpital Saint Antoine, AP-HP, Paris, France.ORCID http://orcid.org/0000-0002-3474-0002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymphodepleting conditioning (LD) with fludarabine and cyclophosphamide is critical to ensure optimal expansion and persistence of CD19 CAR T-cells. We conducted a retrospective EBMT registry study to assess the impact of fludarabine dosing in LD on outcomes in large B-cell lymphoma (LBCL). Among 1498 patients treated between 2019 and 2023 with tisagenlecleucel (tisa-cel; n = 549) or axicabtagene ciloleucel (axi-cel; n = 949), we observed marked variability in fludarabine dosing for tisa-cel, whereas axi-cel was consistently administered at standard doses. In the tisa-cel cohort, higher fludarabine dosing (82.6-120 mg/m

Indexed as

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseVidarabineAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomefludarabineVidarabine

Identifiers

PMID42251173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.